Close Menu

You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.

Home › Business, Policy & Funding › Business News › Biocartis, Amgen Sign CDx Development Deal for Idylla RAS Biomarker Tests

Biocartis, Amgen Sign CDx Development Deal for Idylla RAS Biomarker Tests

Dec 04, 2017
|
staff reporter

NEW YORK (GenomeWeb) – Biocartis announced today that it has signed a companion diagnostic development agreement with Amgen for its Idylla RAS biomarker tests.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

What's Popular?

In Business News

  1. FDA Grants Emergency Use Authorization for Innovita Biological Coronavirus Antibody Test

  2. Illumina, New York Healthcare Providers, NYGC Partner on Clinical Whole-Genome Sequencing

  3. Ravgen Sues Illumina, Roche Alleging Infringement of Cell-Free DNA Testing Patents

  4. Cepheid, Roche Coronavirus Tests Get FDA Emergency Use Authorization

  5. Aetna Updates Noninvasive Prenatal Testing Coverage Policy to Include All Pregnancies

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2020 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.